Technology ID

Human Antibodies Against Middle East Respiratory Syndrome Coronavirus

Lead Inventor
Dimitrov, Dimiter (NCI)
Ying, Tianlei (NCI)
Ju, Tina (NCI)
Yuen, Kwok (University of Hong Kong (HKU))
Therapeutic Areas
Infectious Disease
Development Stages

No effective therapeutics or vaccines against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) are available. The human-to-human aspect of transmission and the high mortality rate associated with MERS-CoV infection have raised concerns over the potential for a future MERS-CoV pandemic and emphasized the need for development of effective therapeutics and vaccines.

The MERS-CoV-S protein is believed to be required for binding and virus entry during MERS-CoV infection. The antibodies of this technology represent candidate antibody-based therapeutics for treatment of MERS-CoV infection.  Researchers at the NCI have developed human antibodies that target MERS-CoV.  Certain of these antibodies bind with epitopes of the MERS-CoV receptor binding domain (RBD) of MERS-CoV spike (S) protein with high affinity and are capable of neutralizing the virus as demonstrated in a pseudovirus assay.

Competitive Advantages:

  • No vaccine or other biologic therapy is available, and this antibody provides high binding (sub-nanomolar) affinity, and relative safety with long half-lives.

Commercial Applications:

  • Antibody-based therapeutics for treatment of MERS-CoV infection
Licensing Contact: